Načítá se...

Selective RET kinase inhibition for patients with RET-altered cancers

BACKGROUND: Alterations involving the RET kinase are implicated in the pathogenesis of lung, thyroid and other cancers. However, the clinical activity of multikinase inhibitors (MKIs) with anti-RET activity in RET-altered patients appears limited, calling into question the therapeutic potential of t...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Ann Oncol
Hlavní autoři:	Subbiah, V, Velcheti, V, Tuch, B B, Ebata, K, Busaidy, N L, Cabanillas, M E, Wirth, L J, Stock, S, Smith, S, Lauriault, V, Corsi-Travali, S, Henry, D, Burkard, M, Hamor, R, Bouhana, K, Winski, S, Wallace, R D, Hartley, D, Rhodes, S, Reddy, M, Brandhuber, B J, Andrews, S, Rothenberg, S M, Drilon, A
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Oxford University Press 2018
Témata:	Original Articles
On-line přístup:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6096733/ https://ncbi.nlm.nih.gov/pubmed/29912274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy137
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo otaguje tento záznam!

Selective RET kinase inhibition for patients with RET-altered cancers

Podobné jednotky